Commentary

Video

Translating BTK Inhibitor Data into Clinical Decision-Making

Author(s):

Mazyar Shadman, MD, MPHMarc S. Hoffmann, MD

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss how to use data for BTK inhibitors to inform clinical decisions in chronic lymphocytic leukemia.

Related Videos
Kathleen A. Dorritie, MD
Rahul Banerjee, MD, FACP
Rahul Banerjee, MD, FACP
Rahul Banerjee, MD, FACP
Alexey Danilov, MD, PhD
John Seymour, MBBS, FRACP, PhD
A panel of 5 experts on CLL
A panel of 5 experts on CLL
A panel of 5 experts on CLL
Rahul Banerjee, MD, FACP
Related Content
Javier Pinilla-Ibarz, MD, PhD, senior member, head, Lymphoma Section, Department of Malignant Hematology, Moffitt Cancer Center
September 9th 2024

Zanubrutinib Associated With Lower Switching Rates vs Other Covalent BTK Inhibitors in CLL/SLL

Oncology Unplugged
August 7th 2024

Park and Grivas Expand on Treatment Updates in Bladder Cancer

Rahul Banerjee MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
September 2nd 2024

Growth in the Multiple Myeloma Treatment Armamentarium Diversifies Treatment Strategies

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Consuelo Bertossi, MD, assistant doctor, Division of CLL, Department of Internal Medicine III, Ulm University Hospital
August 29th 2024

TP53 Mutations Have Strong Prognostic Value for PFS and OS Outcomes in CLL

Rahul Banerjee MD, FACP, physician-researcher, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
August 27th 2024

Bispecific Antibody De-Escalation: Varying Dosing Strategies Aim to Improve Safety, Maintain Efficacy in R/R Myeloma